<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./10_1101_2020_03_30_016147v1/results/search/disease/results.xml">
  <result pre="Since the first clinical use of a VEGF antagonist for" exact="cancer" post="and vascular eye disease more than a decade ago("/>
  <result pre="clinical use of a VEGF antagonist for cancer and vascular" exact="eye disease" post="more than a decade ago( 1), there has been"/>
  <result pre="To date, ANG-TIE-targeted drugs have been tested in patients with" exact="cancer" post="as well as in patients with retinal vascular diseases"/>
  <result pre="in patients with retinal vascular diseases such as wet age-related" exact="macular degeneration" post="(wAMD) and diabetic macular oedema (DMO) ( 2). In"/>
  <result pre="vascular destabilization that occurs in severe infectious conditions such as" exact="pneumonia" post="from flu or coronavirus. Indeed, several clinical studies confirm"/>
  <result pre="et al. ( 2016) Angiopoietin receptor TEK mutations underlie primary" exact="congenital glaucoma" post="with variable expressivity. The Journal of Clinical Investigation 126("/>
  <result pre="al. ( 2016) Angiopoietin receptor TEK mutations underlie primary congenital" exact="glaucoma" post="with variable expressivity. The Journal of Clinical Investigation 126("/>
 </snippets>
</snippetsTree>
